Zydus Lifesciences has launched a real-world data registry trial to determine the benefits of its liver drug, Saroglitazar Magnesium, on patients with non-alcoholic fatty liver disease and associated ailments. Between 1,500 male and female NAFLD patients are expected to be enrolled in the study, with each participant expected to be traced for around 56 weeks.
